Obesity Drug Access, Compounding and Clinical Advances

GLP-1 access is expanding through Medicare, retail delivery, and new formulations while Medicaid and employer coverage remain uncertain. A study reported a small observational association with sudden vision loss—about three to four extra cases per 10,000 over 18 months—but causality is unproven; FDA enforcement, compounding law, API supply, and Lilly's legal dispute remain active.